GB2199032A - Pharmaceutical compounds and their preparation - Google Patents
Pharmaceutical compounds and their preparation Download PDFInfo
- Publication number
- GB2199032A GB2199032A GB08726328A GB8726328A GB2199032A GB 2199032 A GB2199032 A GB 2199032A GB 08726328 A GB08726328 A GB 08726328A GB 8726328 A GB8726328 A GB 8726328A GB 2199032 A GB2199032 A GB 2199032A
- Authority
- GB
- United Kingdom
- Prior art keywords
- added
- indole
- methyl
- reaction
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 81
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 19
- 239000001257 hydrogen Substances 0.000 claims abstract description 19
- 125000006239 protecting group Chemical group 0.000 claims abstract description 15
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract description 7
- 239000000543 intermediate Substances 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 49
- 239000007787 solid Substances 0.000 description 47
- 239000000243 solution Substances 0.000 description 42
- 238000006243 chemical reaction Methods 0.000 description 41
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 38
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 28
- 238000000746 purification Methods 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 25
- 239000000203 mixture Substances 0.000 description 25
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 22
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 21
- 238000003756 stirring Methods 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 18
- 238000010992 reflux Methods 0.000 description 16
- 239000002904 solvent Substances 0.000 description 15
- 238000001665 trituration Methods 0.000 description 15
- 238000001704 evaporation Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 239000002253 acid Substances 0.000 description 12
- 230000008020 evaporation Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 11
- 239000006260 foam Substances 0.000 description 11
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 11
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- XJOOMMHNYOJWCZ-UHFFFAOYSA-N Agroclavine Natural products C1=CC(C2C=C(C)CN(C2C2)C)=C3C2=CNC3=C1 XJOOMMHNYOJWCZ-UHFFFAOYSA-N 0.000 description 8
- UPKBEIIDYOMDQW-UKRRQHHQSA-N agroclavine Chemical group C1=CC=C2[C@H]3C=C(C)CN(C)[C@@H]3CC3=CN=C1[C]32 UPKBEIIDYOMDQW-UKRRQHHQSA-N 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- -1 -OH Inorganic materials 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 125000001931 aliphatic group Chemical group 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000001117 sulphuric acid Substances 0.000 description 6
- 235000011149 sulphuric acid Nutrition 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- KMAKOBLIOCQGJP-UHFFFAOYSA-N indole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CNC2=C1 KMAKOBLIOCQGJP-UHFFFAOYSA-N 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000005708 Sodium hypochlorite Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 229960005076 sodium hypochlorite Drugs 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- AWFDCTXCTHGORH-HGHGUNKESA-N 6-[4-[(6ar,9r,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carbonyl]piperazin-1-yl]-1-methylpyridin-2-one Chemical class O=C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC(Br)=C(C=34)C2)C1)C)N(CC1)CCN1C1=CC=CC(=O)N1C AWFDCTXCTHGORH-HGHGUNKESA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 102000003946 Prolactin Human genes 0.000 description 3
- 108010057464 Prolactin Proteins 0.000 description 3
- 229910000564 Raney nickel Inorganic materials 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 229910045601 alloy Inorganic materials 0.000 description 3
- 239000000956 alloy Substances 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 239000012285 osmium tetroxide Substances 0.000 description 3
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 229940097325 prolactin Drugs 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- BAPLXNMTCVOMGO-UHFFFAOYSA-N N-[10-(benzenesulfonyl)-3,5-dimethyl-5,10-diazatetracyclo[6.6.1.02,6.011,15]pentadeca-1(15),8,11,13-tetraen-7-ylidene]hydroxylamine Chemical compound C1(=CC=CC=C1)S(=O)(=O)N1C=C2C=3C(=CC=CC13)C1C(CN(C1C2=NO)C)C BAPLXNMTCVOMGO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- XSXHWVKGUXMUQE-UHFFFAOYSA-N dioxoosmium Chemical compound O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- IGXWTCBRVQAMAY-UHFFFAOYSA-N 10-(benzenesulfonyl)-3-ethyl-5-methyl-5,10-diazatetracyclo[6.6.1.02,6.011,15]pentadeca-1(15),8,11,13-tetraene Chemical compound C=12C3=CC=CC=1C1C(CC)CN(C)C1CC2=CN3S(=O)(=O)C1=CC=CC=C1 IGXWTCBRVQAMAY-UHFFFAOYSA-N 0.000 description 1
- LKWHFVCRSBMJOL-UHFFFAOYSA-N 10-(benzenesulfonyl)-5-methyl-5,10-diazatetracyclo[6.6.1.02,6.011,15]pentadeca-1(15),2,8,11,13-pentaene-3-carboxylic acid Chemical compound CN1CC(C(O)=O)=C(C=2C=CC=C3C4=2)C1CC4=CN3S(=O)(=O)C1=CC=CC=C1 LKWHFVCRSBMJOL-UHFFFAOYSA-N 0.000 description 1
- OQRDMJFEAZERCB-UHFFFAOYSA-N 10-(benzenesulfonyl)-5-methyl-5,10-diazatetracyclo[6.6.1.02,6.011,15]pentadeca-1(15),8,11,13-tetraene-3-carbonitrile Chemical compound CN1CC(C#N)C(C=2C=CC=C3C4=2)C1CC4=CN3S(=O)(=O)C1=CC=CC=C1 OQRDMJFEAZERCB-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FKYITZGMEZKOPP-UHFFFAOYSA-N 3-ethyl-5-methyl-5,10-diazatetracyclo[6.6.1.02,6.011,15]pentadeca-1(15),8,11,13-tetraene Chemical compound C1=CC(C2C(CC)CN(C)C2C2)=C3C2=CNC3=C1 FKYITZGMEZKOPP-UHFFFAOYSA-N 0.000 description 1
- YNQKKCWJZLKDPM-UHFFFAOYSA-N 4-benzenesulphonyl-9-hydroxymethyl-7-methyl-6,6a,7,8,9,9a-hexahydro-4h-indolo[6,5,4-cd]indole Chemical compound CN1CC(CO)C(C=2C=CC=C3C4=2)C1CC4=CN3S(=O)(=O)C1=CC=CC=C1 YNQKKCWJZLKDPM-UHFFFAOYSA-N 0.000 description 1
- FHBXMXYNMVZULO-UHFFFAOYSA-N 5-methyl-5,10-diazatetracyclo[6.6.1.02,6.011,15]pentadeca-1(15),8,11,13-tetraene-3-carboxamide Chemical compound C1=CC(C2C(CN(C2C2)C)C(N)=O)=C3C2=CNC3=C1 FHBXMXYNMVZULO-UHFFFAOYSA-N 0.000 description 1
- VLHJBCJSWPCWSZ-UHFFFAOYSA-N 9-acetamido-4-benzenesulphonyl-7-methyl-6,6a,7,8,9,9a-hexahydro-4h-indolo[6.5.4-cd]indole Chemical compound CN1CC(NC(C)=O)C(C=2C=CC=C3C4=2)C1CC4=CN3S(=O)(=O)C1=CC=CC=C1 VLHJBCJSWPCWSZ-UHFFFAOYSA-N 0.000 description 1
- ABMGBDWHUCGHRQ-UHFFFAOYSA-N 9-acetyl-4-benzenesulphonyl-7-methyl-6,6a,7,8,9,9a-hexahydro-4h-indolo[6,5,4-cd]indole Chemical compound CN1CC(C(C)=O)C(C=2C=CC=C3C4=2)C1CC4=CN3S(=O)(=O)C1=CC=CC=C1 ABMGBDWHUCGHRQ-UHFFFAOYSA-N 0.000 description 1
- LGSODFMILPDNKI-UHFFFAOYSA-N 9-amino-7-methyl-6,6a,7,8,9,9a-hexahydro-4h-indolo[6.5.4-cd]indole Chemical compound C1=CC(C2C(N)CN(C2C2)C)=C3C2=CNC3=C1 LGSODFMILPDNKI-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 238000006237 Beckmann rearrangement reaction Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 238000010475 Pinacol rearrangement reaction Methods 0.000 description 1
- 240000008154 Piper betle Species 0.000 description 1
- 235000008180 Piper betle Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000012505 colouration Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000020335 dealkylation Effects 0.000 description 1
- 238000006900 dealkylation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- KHDOTPVDSFBNMG-UHFFFAOYSA-N ethanol;pyridine Chemical compound CCO.C1=CC=NC=C1 KHDOTPVDSFBNMG-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- LIESWFVUMISXMT-UHFFFAOYSA-N ethyl 5-methyl-5,10-diazatetracyclo[6.6.1.02,6.011,15]pentadeca-1(15),8,11,13-tetraene-3-carboxylate Chemical compound C1=CC(C2C(C(=O)OCC)CN(C)C2C2)=C3C2=CNC3=C1 LIESWFVUMISXMT-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 150000002913 oxalic acids Chemical class 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- KRLLUZSLSSIQKH-UHFFFAOYSA-N pyrrolo[3,2-c]carbazole Chemical group C12=CC=CC=C2N=C2C1=C1N=CC=C1C=C2 KRLLUZSLSSIQKH-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/02—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hydrocarbon or substituted hydrocarbon radicals, attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/10—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hetero atoms directly attached in position 8
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
There are disclosed compounds of the formula: <IMAGE> in which R<2> is hydrogen, C1-4 alkyl or a protecting group, R<3> is C1-4 alkyl or a protecting group, and X is hydrogen or -OX is a leaving group, which are intermediates in the preparation of pharmaceutical compounds.
Description
PHARMACEUTICAL COMPOUNDS AND THEIR PREPARATION This invention relates to novel pharmaceutical compounds and a novel process by which they may be prepared.
The literature describes many compound having the ergoline nucleus:
and compounds of this type have been found to possess a surprising variety of pharmacological activities. One such ergoline found in nature is agroclavine, the compound bearing a methyl substituent at positions 7 and 9 and an ethylenic unsaturation in the 9,10 position.
The present invention provides a new indoloindole structure derived from agroclavine and related ergoline compounds.
The compounds of the invention are of the formula
in which R 1 is an aliphatic or aromatic function, and R2 and R3 are each hydrogen, C1-4 alkyl or a protecting group; and salts thereof. The compounds having optimum biological activity are 2 3 the unprotected compounds, that is, those in which R and R are hydrogen or C1-4 alkyl.
The compounds of the invention represent a novel type of structure in which the six-membered During of such compounds as agroclavine, is replaced by a 5-membered ring. They have been found to affect the levels of prolactin in rats and are thus indicated for use in the treatment of disorders of the central nervous system.
In the above formula R1 can be an aliphatic or aromatic function and such groups may be chosen from a wide range, of which examples are as follows:
(i) a substituent of the formula R'CO- where R' is C14 alkyl, especially CE3CO-, (ii) a group of the formula
where R' is hydrogen or C14 alkyl, X is -OH or (iii) a group of the formula
where R' is hydrogen or C14 alkyl, X is -NOH, -SCH2CH2S-, mNNH2 or aNNHR" where R" is
C1-4 alkyl or optionally substituted phenyl,
(iv) a C1-5 alkyl group,
(v) a substituent of the formula -COZ where Z can be hydrogen, -OH, halogen especially chlorine, -OC1- 4 alkyl, -OC14 alkylphenyl, -N3, -NH2, -NHR', -NR 2 where each R' group is C1-4 alkyl,
(vi) an -NH2, -NHR' or -NR'2 group or a group of the formula -NHCOR' where R' is C1,4 alkyl, (vii) a nitrile (-CN) group, and
(viii) a group of the formula -C(OH)(CH3)R' where R' is optionally substituted phenyl. R1 is preferably an aliphatic group and especially one chosen from (i), (iv) and (v) above.
Reference to such groups as C1,4 alkyl is intended to include both straight and branched chain groups, such as for example, methyl, ethyl, propyl, isopropyl, butyl and tert. butyl.
An optionally substituted phenyl group is phenyl or phenyl substituted with one or more, preferably one to three substituents, selected from for example, C14 alkyl especially methyl, C14 alkoxy especially methoxy and ethoxy, nitro, cyano, hydroxy, halo and'amino.
As mentioned above, R2 and R3 are each hydrogen, C14 alkyl or a protecting group. A protecting group can be any group conventionally employed to protect a nitrogen on an indole nucleus.
Such groups are well known and are discussed, for example, by R.J.
Sundberg and H.F. Russell J.O.C. 38, 3324 (1973). They include groups of the formula R'CO where R' is C14 alkyl, optionally substituted phenyl or optionally substituted phenyl C1,4 alkyl, particularly preferred examples being acetyl, benozyl, and especially benzenesulphonyl or toluenesulphonyl.
Salts of the compounds of this invention include pharmaceutically-acceptable acid addition salts such as salts derived from non-toxic inorganic acids, for example, hydrochloric acid, nitric acid, phosphoric acid, sulphuric acid, hydrobromic acid, hydriodic acid and phosphorous acid, as well as salts derived from non-toxic organic acids such as aliphatic mono and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic and hydroxyalkandioic acids, aromatic acids, aliphatic and aromatic sulphonic acids.As well as pharmaceutically-acceptable salts, other salts are also included within the scope of acid addition salts such as, for example, those with picric or oxalic acids; they may serve as intermediates in the purification of the compounds or in the preparation of other, for example pharmaceutically-acceptable, acid addition salts, or are useful for identification, characterisation or purification of the bases. When the compound of the invention contains an acid group, for example when R1 is -COOH, cationic salts can be prepared such as inorganic salts formed with alkali or alkaline earth betel metals especially sodium and potassium, or organic base salts such as ammonium or tetramethylammonium.Furthermore, the zwieterionic form of the compounds formed with an amino function and a carboxy group, is also included in the term "salt".
Preferred compounds of formula (I) are those in which R1 is an aliphatic or aromatic function, R2 is hydrogen, C14 alkyl or a protecting group and R3 is C14 alkyl; and acid addition salts thereof. Of these compounds three groups are especially preferred 1 2
(a) those in which R is CH3CO-, R is hydrogen or a protecting group and R3 is C14 alkyl especially methyl, such compounds being intermediates in the preparation of other compounds of formula (I),
(b) those in which R1 is -COOC, alkyl, especially compounds in which R1 is -COOCH3, R2 is hydrogen or a protecting group and R3 is C14 alkyl especially methyl, such compounds being of special practical use, and
(c) those in which R1 is ethyl, R2 is hydrogen or a protecting group and R3 is C 1-4 alkyl especially methyl.
The compounds of formula (I) are prepared by a novel method which involves the initial preparation of the compound in which the substituent R1 is CH3CO-, which in turn can be converted to other aliphatic or aromatic functions. Thus the invention includes a process for preparing a compound of formula (I) above, which comprises the rearrangement of a compound-of the formula
in which R2 is as defined above and R is C1-4 alkyl or a protecting group, and -OX is a leaving group, to give a compound of formula (I) in which R1 is -COCH3, and optionally converting the R1 group to another aliphatic or aromatic function, or 2 3 removing an R or R group when it is a protecting group.
The compounds of formula (II) undergo a pinacolpinacolone rearrangement as described in Comprehensive Organic
Chemistry (The Synthesis and Reactions of Organic Compounds)
Pergamon Press 1979 Vol. 1, p.688. The compound of formula (II) bearing a leaving group X on the 10-hydroxy substituent gives a compound of formula (I) when treated preferably with a base such as pyridine. Suitable X groups include, for example, groups of the formula R1S02 in which R1 is C14 alkyl or optionally substituted phenyl, for instance, methane sulphonate.
The process of the invention is preferably carried out at a temperature of from 0 C to 100 C, for example, from 10 C to 60 C and in an inert organic solvent. When a base such as pyridine is employed which is a solvent for the reaction, excess base may be employed.
Compounds of formula (I) in which R3 is hydrogen can also be prepared by dealkylation of compounds in which R takes an appropriate value such as for example ethyl.
Compounds of formula (II), and the free 10-hydroxyl compound (X is hydrogen), are novel compounds and are included as part of the present invention. The former can be prepared simply by reaction of the free l0-hydroxyl compound with the appropriate reagent, for example R S02C1.In its turn the compound of formula (II) (X is hydrogen) can be prepared by oxidising a compound of the formula:
This oxidation step is preferably performed in a suitable inert organic solvent such as for example diethyl ether at a temperature of from 0 C to 40"C. Suitable oxidising agents include osmium tetroxide in stoichiometric amounts in an inert atmosphere such as nitrogen, or in catalytic amounts in the presence of a co-oxidant such as for example described in Comprehensive Organic Chemistry (The Synthesis and Reactions of Organic Compounds) Pergamon Press 1979, Vol.1, P.164, for instance N-methylmorpholine-N-oxide.
It will be appreciated that the compound of formula (III) in which R2 is hydrogen is the known clavine alkaloid, agroclavine. Other starting materials in which R2 and/or R3 is C14 alkyl or a protecting group can be prepared by reaction of agroclavine or noragroclavine with the appropriate C1,4 alkyl halide or with a suitable protecting group-donating compound by standard methods.
Similarly, it will be appreciated that compounds of formula (I) in which R2 is hydrogen can be prepared by removal of a protecting group from the nitrogen atom by the use, for example, of potassium hydroxide and ethanol. R1 groups can be derived from the compound in which R1 is -COCH3 by conventional methods known in the art, as for instance illustrated in the following
Examples.
As mentioned above, compounds of the invention have useful central nervous system activity and low toxicity. This activity has been confirmed by their ability to alter serum prolactin levels in rats according to the test described by
Clemens J.A. Smalstig E.B. and Sawyer B.D. (1974) Psychopharma cologia Vol.40, p.123.
The following compounds significantly (p < 0.05) reduced the prolactin levels in reserpinised rats, by more than 20%, at dosages of 100 ugSkg i.p.,
R1 - COCH3 - CH 2CH3
- CON-H2
- NHCOCH.3
- CH2 OH - CON(C2H5)2
A positive result in the above test indicates that the compounds possess dopamine agonist activity which is indicative of use in the treatment of, for example, parkinsonism and hyperprolactinemia states.
The compounds are effective over a wide dosage range, the actual dose administered being dependent on such factors as the particular compound being used, the condition being treated and the type and size of mammal being treated. However, the dosage required will normally fall within the range of 0.05 to 10 mg/kg per day, for example in the treatment of adult human dosages of from 0.2 to 5 mg/kg may be used.
The compounds and pharmaceutically-acceptable salts of the invention will normally be administered orally or by injection and, for this purpose, said compounds and salts will usually be utilised in the form of a pharmaceutical composition. Such compositions are prepared in a manner well known in the pharmaceutical art and normally comprise at least one active compound or pharmaceutically-acceptable salt of the invention associated with a pharmaceutically-acceptable carrier therefor. In making the compositions of the present invention, the active ingredient will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container. ' When the carrie serves as a diluent, it may be a solid, semi-solid or liquid material which acts as a vehicle, excipient or medium for the active ingredient.
Some examples of suitable carriers are lactose, dextrose, sucrose, sorbitol, mannitol, stargesh, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, syrup, methyl cellulose, methyl and propylhydroxybenzoate, talc, magnesium stearate or mineral oil. The compositions of the invention may, as is well-known in the art, be formulation so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient.
Depending on the route of administration, the foregoing compositions may be formulation as tablets, capsules or suspensions for oral use and injection solutions for parenteral use. Preferably the compositions are formulated in a dosage unit form, each dosage containing from 1 to 200 mg more usually 5 to 100 mg, of the active ingredient.
The invention is illustrated by the following Examples.
EXAMPLE 1 4-Benzenesulphonyl-7,9-dFmethyl-4,6,6a,7 [4,3-fgj quinoline To a solution of agroclavine (9.0 g) in dichloromethane (150cm ) at 0 C under nitrogen was added with stirring aqueous
3 sodium hydroxide (45 cm , 50X w/w) and a solution of tetra-N-butylammonium hydrogen sulphate (1.462 g) in dichloromethane (50cm ). After 0.5 hours a solution of benzenesulphonyl chloride (6.2cm3) in dichloromethane (25cm3) was added over a period of 15 minutes, the temperature being maintained at OOC. The mixture was allowed to warm to room temperature and stirred for 16 hours.
To the reaction was added water (500cm3) and dichloromethane (500cm3), the phases separated and the aqueous layer was re-extracted with dichloromethane (2 x 125cm3). The combined extracts were washed with aqueous sodium hydroxide (2 x 500cm3,
M), water (2 x 250cm ) and dried before evaporating under vacuum.
Trituration of the resultant brown oil with diethyl ether yielded the title compound as an off-white foam, m.p. 80-81oC (dec).
EXAMPLE 2 9,10-Dihydroxy-7,9-dimethYl-4 J 6,6a,7,8,9,10,10a-octahydroindolo [4,3,-fg] quinoline To a stirred solution of agroclavine (0.90 g) in dry ethanol-pyridine (20cm3, 1:3) under nitrogen was added a solution of osmium tetroxide (1.00 g) in'dry diethyl ether (50cm3). The solution immediately became dark brown in colour and after 5 hours reaction was indicated to be complete. Hydrogen sulphide was bubbled through the stirred solution causing complete precipitation of a black solid (osmium IV salt) in 4 hours. The precipitate was removed on a Kieselguhr bed filter and washed with ethanol (2 x 20cm3); evaporation under vacuum of the combined filtrate gave a dark red solid.
Purification on silica gel 60 eluted with chloroformmethanol (4:1), yielded the title compound as an off-white solid, m.p. 148-1520C (dec).
EXAMPLE 3 4-BenzenesulphoDyl-9,10-dthydroxy-7,9-dflmethyl-4,6,6a,7,8,9,10,10a- octahydroindolo [4,3,-f g] quinoline N-Benzenesulphonyl agroclavine (1.48 g) was dissolved under nitrogen in dry, degassed pyridine (lOcm3). Diethyl ether (75cm3) was added with stirring followed by a solution of osmium tetroxide (1.0 g) in diethyl ether (20cm ). A copious brown precipitate formed and the mixture was left to stir for 16 hours.
Addition of a solution of sodium hydrogen sulphite (1.628 g) in ethanol-water (40cm3, 1:1) gave a clear orange coloured solution containing a heavy brown precipitate of osmium (IV) oxide.
After 5 hours the solution was filtered, the solvents evaporated under vacuum and the orange residue partitioned between chloroform (150cm ) and water (150cm ). The separated aqueous layer was re-extracted with chloroform (4 x 40cm3) and the combined extracts washed with water (50cm3), dried and evaporated under vacuum to give an orange gum. Trituration with diethyl ether gave an impure product as a dark yellow foam.
Purification on silica gel 60 eluted with chloroformmethanol (12:1) yielded the title compound as a pale cream foam m.p. 120-1220C.
EXAMPLE 4 9-Acetyl-4-benzenesuIphonyl-7-methyl-6,6 indolo [6,5,4-cd indole
The diol of Example 3 (1.00 g) was dissolved in dry 3 pyridine (4cm ), an excess of 4A molecular sieve (0.5 g) added and stirred solution cooled to OOC. After 10 minutes, methane sulphonyl chloride (0.097cm3) was added and stirring continued for 16 hours.
Chloroform (100cm3) and water (200cm3) were added and the mixture partitioned. The separated aqueous layer was reextracted with chloroform (3 x 50cm3) and the combined extracts washed with aqueous sodium hydroxide (2 x 50cm3, M) and water (100cm3) before drying. Evaporation of the filtrate under vacuum gave a tan coloured foam.
Purification on silica gel 60 eluted with chloroformmethanol (20:1) yielded the title compound as a white foam, m.p.
76-790C.
EXAMPLE 5 9-Acetyl-4-benzenesulphonyl-7-methyl-6,6a,7,8,9,9a-hexahydro-4H- indolo [6,5,4-cd] indole-9-dithioketal
The 9-acetyl compound of Example 4 (0.211 g) was dissolved with stirring into ethanedithiol (0.25cm3) and boron trifluoride diethyletherate (0.25cm3) added causing gaseous evolution. After stirring for 12 hours the reaction was indicated to be complete, and all solvents were removed under vacuum. Repeated high vacuum trituration with methanol gave impure product (0.415 g) as a sticky white solid.
Purification on silica gel 60 eluted with chloroformmethanol (5:1) gave, after trituration with diethyl ether, the title compound as a white solid, m.p. 89-91 C (dec).
EXAMPLE 6 4-Benzenesulphonyl-9-ethyl-7-methyl-6,6a,7,8,9,9a-hexahydro-4H- indolo [6,5,4-cd] indole
To the dithioketal of Example 5 (0.259 g) and Raney nickel catalyst, 50 micron grade, (3.5 g) was added ethanol (20cm3) the resultant stirred suspension was heated to reflux.
After 5 hours all starting material was indicated to have been consumed. To the cooled reaction was added chloroform (20cm3) and the mixture vigorously shaken and filtered. The residue was further extracted with chloroform-methanol (2 x 20cm , 5:1) and the combined extracts evaporated under vacuum to give a dark green solid.
Purification on silica gel 60 eluted with chloroformmethanol (5:1) gave the title compound as a yellow-white smear which could not be crystallised.
EXAMPLE 7 9-Ethyl-7-methyl-6,6a,7,8,9,9a-hexahydro-4H-indolo [6,5,4-cd] indole
To a stirred solution of the compound of Example 6 (0.0965 g) in ethanol (3cm3) was added potassium hydroxide (0.036 g) and the reaction heated to reflux. After 3 hours reaction was indicated to be complete, and the product was isolated as described in Example 6.
Purification on silica gel 60 eluted with chloroformmethanol (5:1) gave, after trituration with dichloromethane, the title compound as a white solid, m.p. 137-139 C (dec).
Exvr r 4-Benzenesulphonyl-7-methyl-9-methyloximino-6, 6a, 7,8,9, 9a-hexa- hydro-4H-indolo [6,5,4-cd] indole
To a stirred solution of the 9-acetyl compound of
Example 4 (0.25 g) in methanol (12cm3) was added anhydrous sodium acetate (0.078 g) and hydroxylamine hydrochloride (0.0615 g) and the orange solution heated to reflux. After 5 hours reaction was indicated to be complete, all solvents were removed under vacuum.
Chloroform (40cm3) and water (40cm ) was added and the residue partitioned. The organic layer was re-washed with water (25cm3), dried and evaporated under vacuum to give a yellow-white solid.
Purification on silica gel 60 eluted with chloroformmethanol yielded the syn ketoxime as an off-white foam, m.p.
160-1620C (dec), and the anti ketoxime as a cream coloured solid, m.p. 129-1320C (dec).
EXAMPLE 9 4-Benzenesulphonyl-7-methyl-9-methyloximino-6 , 6a,7,8,9, 9a-hexa- hydro-4H-indolo [6,5,4-cd] indole-/-p-toluenesulphonate The 9-acetyl compound of Example 4 (0.15 g) was converted into the impure ketoximes of Example 8 by the procedure previously described.
To a vigorously stirred solution of the ketoximes (0.181 g) in chloroform (5cm3) was added 3.75 M aqueous sodium hydroxide (0.305cm ). After 5 minutes, to the slowly clearing solution was added p-toluenesulphonyl chloride (0.127 g) and the reaction left to stir. After 2 days the reaction was indicated to be complete.
Water (20cm3) and chloroform (30cm3) were added and the mixture partitioned, the aqueous layer was re-extracted with chloroform (20cm3) and the combined extracts washed with saturated aqueous sodium hydrogen carbonate (2 x 25cm3) and water (25cm3), and dried. Evaporation under vacuum of the yellow filtrate yielded the title compound, after trituration with diethyl ether, as an off-white foam, m.p. 95-990C (dec).
EXAMPLE 10 9-Acetamido-4-benzenesulphonyl-7-methyl-6, 6a, 7,8,9, 9a-hexahydro- 4H-indolo [6.5.4-cd] indole - Beckmann Rearrangement
To a stirred solution of the syn ketoxime of Example 8 (0.141 g) in dry pyridine (3cm3) at 0 C was added phosphorus oxychloride (0.32cm3). The reaction was left to stir at OOC for 1 hour at room temperature for 16 hours before being acidified to pH 1 with concentrated hydrochloric acid. Water (50cm3) was added and the solution extracted with chloroform (3 x 30cm3), the combined extract was washed with saturated aqueous sodium hydrogen 3 3 carbonate (2 x 25cm ), water (2 x 25cm ) and dried.The aqueous washings were neutralized with saturated aqueous sodium hydrogen carbonate and treated as before and further extracted.
Evaporation under vacuum of the combined filtrate gave, after trituration with diethyl ether, the title compound as a white solid, m.p. 165-1670C (dec).
EXAMPLE 11 9-Acetamido-7-methyl-6,6a,7 ,8,9,9a-hexahydro-4H-indolo [6,5,4,-cd] indole
The N-benzenesulphonyl-9-acetamide of Example 10 (0.131 g) was debenzenesulphonylated with potassium hydroxide in refluxing ethanol by the procedure of Example 7.
Purification on silica gel 60 eluted with chloroformmethanol (5:1) yielded the title compound as an off-white solid, m.p. 174-1780C (dec).
EXAMPLE 12
Haloform oxidation of the 9-acetyl compound of Example 4 The aqueous sodium hypochiorite solution was assayed prior to use in the reaction.
To a stirred solution of the 9-acetyl compound (0.919 g) in methanol (25cm3) at 0 C was added 3 M aqueous sodium hydroxide (0.78cm3) and 2.23 M aqueous sodium hypochlorite (2.089cm3), dropwise causing a lightening of reaction colour. The reaction was allowed to warm slowly to room temperature and after 2.5 hours further 2.23 M aqueous sodium hypochlorite (1.55cm3) added.
After 20 hours reaction was indicated to be complete.
All solvents were removed under vacuum to give a yelloworange solid to which water (20cm3) was added and the mixture then vigorously stirred. After 10 minutes the resultant orange slurry was cooled to OOC and acidified to pR 1 by the dropwise addition of concentrated hydrochloric acid. Evaporation under vacuum of the acidified mixture gave an orange gum which on trituration with acetone yielded the crude acid contaminated with inorganic material as an orange-brown foam.
Purification on silica gel 60 eluted with chloroformmethanol (1:1) followed by methanol gave, on evaporation under vacuum, a product contaminated by silica gel. Dissolution into chloroform-methanol (10cm3, 1:1), filtration and evaporation under vacuum yielded 4-benzene8ulphonyl-7-methyl-6,6a,7,8,9,9a-hexahydro-4H-indole [6,5,4-cd] indole-9-carboxylic acid in the zwitterionic form as a light tan coloured solid, m.p. 188-1910C (dec), and 4-benzenesulphonyl-7-methyl-6,6a,7,8-tetrahydro-4H-indolo [6.5.4-cd] indole-9-carboxylic acid in its zwitterionic form as a yellow solid, m.p. 195-1990C (dec).
EXAMPLE 13 7-Methyl-6,6a,7,8,9,9a-hexahydro-411-indolo (6.5.4-cd] indole-9carboxylic acid
To a stirred solution of the 9-acetyl compound of
Example 4 (1.00 g) in methanol (30cm3) at OOC was added 3 M aqueous sodium hydroxide (0.085cm3) and 2.2 M aqueous sodium hypochlorite (2.30cm3) causing a visible lightening of reaction colour. The reaction was allowed to warm slowly to room temperature and after 2 hours further 2.2 n aqueous sodium hypo chlorite (2.30cm ) added. After 20 hours reaction was indicated to be complete, all solvents were removed under high vacuum to give a yellow-orange residue.
Ethanol (20cm ) was added with stirring and into the resultant slurry was introduced potassium hydroxide (0.284 g) and the mixture heated to reflux. After 5 hours reaction was indicated to be complete, all solvent was removed under vacuum to give an orange residue. Water (30cm3) was added with stirring and the orange coloured solution cooled to OOC, careful dropwise addition of concentrated hyrochioric acid was made to pR 1. All solvents were removed under high vacuum to give, after trituration with acetone, a dark yellow solid.
Purification on silica gel 60 eluted with methanol yielded the title compound in its zwitterionic form as a tan coloured solid, m.p. 160-1620C (dec).
EXAMPLE 14 4-Benzenesulphonyl-9-carbomethoxy-7-methyl-6,6a,7,8,g,ga-hexahydro- 4H-indolo [6.5.4-cd] indole
To a stirred solution of the sodium salts of the products of Example 12 (0.203 g) in methanol (5cm3) was added concentrated sulphuric acid (0.1cam and the solution heated to reflux. After 2 hours further concentrated sulphuric acid (0.35cm3) was added and the reaction left to reflux for 20 hours.
Evaporation under vacuum of the reaction mixture gave an orange residue. Chloroform (40cm3) and water (40cm3) were added and the residue partitioned. The separated aqueous layer was re-extracted with chloroform (20cm3) and worked up in the usual way to give, after trituration with diethyl ether, the title compound as a pale orange-white foam, m.p. 63-66 C (dec).
EXAMPLE 15 4-Benzenesulphonyl-9-carbobenzyloxy-7-methyl-6,6a,7,8,9,9a-hexa- hydro-4H-indolo [6,5,4,-cd0 indole
Similarly 4-benzenesulphonyl-9-carbobenzyloxy-7-methyl 6,6a,7,8,9,9a-hexahydro-4E-indolo [6,5,4-cd] indole was prepared by acid-catalysed esterification of the products of Example 12 as a yellow gum.
EXAMPLE 16 9-Carbomethoxy-7-methl-6 , 6a, 7,8,9 ,9a-hexahydro-4H-indolo [6.5.4-cd] indole
To a solution of the free indole 3--carboxylic acid (Example 13) (0.203 g) in methanol (5cm3) was added with stirring concentrated sulphuric acid (0.15cm3) and the reaction heated to reflux. After 2 hours further concentrated sulphuric acid (0.1cm3) was added, reaction was indicated to be complete after 15 hours. The resultant solution was allowed to cool to room temperature to give after evaporation under vacuum and trituration with chloroform a dark orange solid (0.329 g).
Purification on silica gel 60 eluted with chloroformmethanol (1:1) yielded the title compound as an off-white solid, m.p. 181-183 C.
EXAMPLE 17 9-Carboethoxy-7-methyl-6,6a, 7,8,9,9a-hexahydro-4H-indolo [6.5.4-cd] indole
To a solution of the free indole 9-carboxylic acid (Example 13) (0.12 g) in ethanol (6cm3) was added with stirring fused -toluenesulphonic acid (0.081 g) and the reaction heated to 50 C. After 15 hours further fused -toluenesulphonic acid (0.081 g) was added and the temperature raised to 60 C. After 3 days reaction was indicated to be complete. All solvent was removed under vacuum.
3
Dichloromethane-methanol (25cm3, 5:1) and water (25cm ) were added and the residue partitioned. The separated aqueous layer was worked up in the usual way to yield the title compound as a dark yellow smear.
A sample was further purified on silica gel 60 eluted with chloroform-methanol (10:1) to give a tan coloured solid, m.p.
100-1040C (dec).
EXAMPLE 18 4-Benzenesulphonyl-7-methyl-6,6a,7,8,9,9a-hexahydro-4H-indolo [6.5. 4-cd] indole-9-carboxamide (a) Method A - With 0.880 ammonia solution
The 9-carboxylic acid (0.142 g) was dissolved in thionyl chloride (0.3cm3) and stirred for 15 minutes, at 0 C. The excess thionyl chloride was removed under vacuum ( < 300 C) and the residue triturated with dry benzene (2cm3) to give the 9-acid chloride as an orange solid.
Concentrated ammonia solution (0.5cm3) was added at OOC with stirring. After 15minutes, dichloromethane (0.5cm3) was added and the remaining solid dissolved. After stirring for 2 hours the solvents were evaporated under vacuum. The resultant orange residue was extracted with chloroform-methanol (3 x 20cm3, 5:1) to give a yellow solid.
Purification on silica gel 60 eluted with chloroformmethanol (1:1) yielded the title compound as a yellow-white solid.
(b) Method B - With anhydrous ammonia
The 9-carboxylic acid (0.50 g) was dissolved in thionyl chloride (1.245cm3) and stirred for 20 minutes at OOC. The excess thionyl chloride was removed under vacuum ( < 30 C) to yield
after trituration with dry benzene (5cm ) the 9-acid chloride as an orange solid.
Into a stirred solution of the acid chloride in dry dichloromethane (7cm3) at OOC under anhydrous conditions was bubbled anhydrous ammonia, causing immediate solid precipitation.
after 30 minutes the ammonia flow was stopped and the mixture evaporated to dryness. Dissolution into dichloromethane-methanol (100cm3, 1:1), filtration and evaporation under vacuum gave the product contaminated with inorganic salts as an orange solid.
Purification on silica gel 60 eluted with chloroformmethanol (1:1) yielded the title compound as a light brown solid.
EXAMPLE 19 4-Benzenesulphonyl-7-methyl-6,6a17,8,9,9 [6.5.4-cd] indole-9-N,N-diethylcarboxamide Using method A as described in the preparation of
Example 18, 4-benzenesulphonyl-7-methyl-6,6a,7,8,9,9a-hexahydro-4H-lndolo [6,5,4-cd] indole-9-N,N-diethylcarboxamide was prepared as an orange-white foam, m.p. 87-900C.
EXAMPLE 20 7-Hethyl-6,6a,7,8,9,9a-hexahydro-4H-indolo [6.5.4,-cd] indole-9carboxamide
The N-benzenesulphonyl 9-carboxamide (Example 18) (0.30 g) was added with stirring to anhydrous ammonia at -450C.
Freshly cut sodium was added in small pieces until the blue colour persisted. After 15 minutes, the ammonia was allowed to evaporate leaving an orange residue. Ethanol (locum3) was added to destroy residual sodium and the solution evaporated to dryness.
The residue was extracted with chloroform-methanol (2 x 20cm3, 2:1), filtered and evaporated to give a product contaminated with inorganic salts as an orange solid.
Purification on silica gel 60 eluted with chloroformmethanol (1:1) yielded the title compound as a light tan-coloured solid, m.p. 163-1660C (dec).
EXAMPLE 21 7-Methyl-6, 6a, 7,8,9, 9a-hexahydro-4H-indolo [6,5, 4-cd]-indole-9-N,N- diethylcarboxamide a) Method A - Sodium-liquid ammonia at -450C
The 4-benzenesulphonyl-9-N,N-diethylamide (Example 19) (0.27 g) was added with stirring to anhydrous ammonia at -450C.
Total solution was not achieved. Freshly cut sodium was added in small pieces until the blue colour persisted. After 20 minutes the ammonia was allowed to evaporate leaving an orange residue, which was worked up as before to give an orange smear.
Purification on silica gel 60 eluted with chloroformmethanol (3:1) yielded the title compound as a light tan coloured solid and 7-methyl-4,6,6a,7,8,9a-hexahydro-indolo [6,5,4-cd] indole-9-carboxamide.
b) Method B - Sodium-dry diethylamine at 200C
The 4-benzenesulphonyl-9-N,N-diethylamide (0.115 g) was added with stirring to anhydrous diethylamine (3cm3) at room temperature. Freshly cut sodium (0.059 g) was added causing no change in colouration. After 60 hours t.l.c. indicated no further changes in reaction composition, all solvents were removed under vacuum. The residue was partitioned between chloroform (25cm3) and water (25cm3) and worked up as before to give on evaporation under high vacuum a dark yellow smear.
Purification on silica gel 60 eluted with chloroformmethanol (10:1) yielded slightly impure compound as a light orange solid and starting material.
c) Method C - Raney-nickel alloy in refluxing ethanol
The 4-benzenesulphonyl-9-N,N-diethylamide (0.072 g) in ethanol (5cm ) was added to a stirred slurry of Raney nickel alloy (0.75 g, 50 grade). The orange suspension was heated to reflux for 4 hours and a further portion of alloy (0.37 g) added. After 24 hours the mixture was allowed to cool before dilution with dichloromethane-methanol (50cm3, 1:1) and filtration under pressure through a Kieselguhr filter bed. The residue was 3 further washed with methanol (2 x 20cm ) and the combined filtrate evaporated under vacuum to give a dark orange smear.
Purification on silica gel 60 eluted with chloroformmethanol (3:1) yielded starting material and title compound as a yellow-white solid, m.p. 142-144 C (dec).
EXAMPLE 22 4-Benzenesulphonyl-9-hydroxymethyl-7-methyl-6,6a,7,8,9, 9a-hexa- hydro-4H-indolo [6,5,4-cd] indole
To a stirred solution of the 9-methyl ester (Example 14) 3 (0.365 g) in dry methanol (4cm ) under anhydrous conditions was added sodium borohydride (0.252 g) causing vigorous effervescence.
After 2 hours further sodium borohydride (0.067 g) was added.
After the initial effervescence had subsided the reaction was heated to 600 C. Reaction was indicated to be complete and after 4 hours water (4cm3) was carefully added and the cloudy mixture allowed to cool to room temperature. The product was extracted from the aqueous solution with chloroform, the combined extract 3 washed with water (50cm ), dried and evaporated under vacuum to yield the title compound as a yellow-white foam, m.p. 124-1270C.
EXAMPLE 23 9-Rydroxymethyl-7-methyl-6,6a,7,8,9,9a-hexahydro-4E-indolo [6,5,4-cd] indole
LAH reduction and debenzensulphonylation
To a stirred solution of the 9-methyl ester (Example 14) (0.25 g) in dry diethyl ether (1Ocm3) under anhydrous conditions was added lithium aluminium hydride (LAH) (0.046 g). After 2 hours further LAR (0.046 g) was added and the reaction heated to reflux, reaction was indicated to be complete after 5 hours.
3
Water (10cm ) was carefully added causing immediate precipitation of a flocculent solid; evaporation under vacuum of the mixture gave a yellow-white residue.
The residue was dissolved with difficulty into ethanol (6cm3) and potassium hydroxide (0.171 g) added with stirring.
After refluxing for 15 hours all solvents were removed under vacuum to give an orange-white solid.
Purification on silica gel 60 eluted with chloroformmethanol (1:1) yielded the title compound as a tan coloured solid, m.p. 121-1250C (dec).
EXAMPLE 24 9-Hydroxymethyl-7-methyl-6,6a,7,8,9,9a-hexahydro-4u-indolo 16,5,4-cd indole
Using the debenzenesulphonylation procedure previously described (Example 22) (0.238 g), reaction with potassium hydroxide in refluxing ethanol yielded the title compound after purification on silica gel 60 eluted with chloroform-methanol (3:1) as a tan coloured solid, m.p. 121-1250C (dec).
EXAMPLE 25 4-Benzenesulphonyl-9-cyano-7-methyl-6, 6a, 7,8,9, 9a-hexahydro-4H-indolo [6.5.4-cd] indole
To a stirred solution of the N-benzenesulphonyl-9carboxamide (Example 18) (0.067 g) in pyridine (2cm3) was added p-toluenesulphonyl chloride (0.161 g) and the reaction heated to 90-100cC. After 4 hours reaction was indicated to be complete, all solvents were removed under vacuum to give a brown smear.
Chloroform (25cm3) and water (25cm3) were added and the residue partitioned; from the extract was isolated an impure product as a dark yellow solid.
Purification on silica gel 60 eluted with chloroform-methanol (10:1) yielded, after trituration with diethyl ether, the title compound as a light orange solid, m.p. 136-1390C (dec).
EXAMPLE 26 9-Cyano-7-methyl-6,6a,7,8,9,Sa-hexahydro-4H-indolo [6.5.4-cd] indole
To a stirred solution of the free indole-9-carboxamide (Example 20) (0.031 g) in dry dimethylformamide (lcm3) under anhydrous conditions at OOC was added thionyl chloride (0.02cm3) with visible reaction. Reaction was indicated to be complete after 20 minutes. Water (5cm3) was added and all solvent removed under high vacuum ( < 30 C) to give an orange smear.
Purification on silica gel 60 eluted with chloroformmethanol (5:1) yielded, after trituration with 40-60 degree petroleum ether, the title compound as a tan coloured solid, m.p.
77-800C (dec).
EXAMPLE 27 9-Amino-7-methyl-6,6a,7,8,9,9a-hexahydro-4H-indolo [6.5.4-cd] indole
To the N-benzenesulphonyl-9-acetamide (Example 10) (0.15 g) was added with stirring hydrazine hydrate (4cm3) and the mixture heated to reflux under anhydrous conditions. After 24 hours all solid had dissolved to give a clear orange solution.
All solvents were removed under high vacuum ( < 300C) to give after trituration with water (10cm ) and acetone (2 x 10cm ) an orange solid.
Purification on silica gel GF254 preparative plates eluted with chloroform-methanol-concentrated onia (20:2:1) gave the title compound as a yellow-orange solid, m.p. 95-970C (dec).
EXAMPLE 28 4-Benzenesulphonyl-9-(1-hydroxyethyl)-7-meth < hexahydro-4H-indolo 16,5,4-cd] indole
To a stirred solution of the 9-acetyl compound (Example 4) (0.10 g) in ethanol (2cm3) was added sodium borohydride (0.0075 g) with visible reaction. After 2 hours reaction was indicated to be complete. Water (20cm3) and dichloromethane (20cm3) were added and the mixture partitioned, the separated aqueous layer was re-extracted with dichloromethane (20cm ) to give, after evaporat- ing under vacuum, a yellow-white solid.
Purification on silica gel 60 eluted with chloroformmethanol (4:1) gave the title compound as a white solid (0.090 g), m.p. 90-92"C.
EXAMPLE 29 9-Acetyl-4-benzenesulphonyl-7-methyl-6, 6a, 7,8,9,9a-hexahydro-4H- indolo [6,5,4-cd] indole 2' ,4 ' -dinitrophenylbydrazone To a stirred solution of the 9-acetyl compound (0.051 g) in ethanol (1cm ) was added a solution of 2,4-dinitrophenylhydrazine (0.0375 g) in ethanol (4cm3) and 98% sulphuric acid (0.15cm3, the latter causing precipitation of solid. The reaction was heated to 60 C and after 1 hour further 2,4-dinitro phenylhydrazine (0.0375 g) added. The product was isolated by extraction with chloroform (20cm3) as a dark yellow-orange solid.
Purification on silica gel 60 eluted with chloroformmethanol (20:1) yielded the title compound as a bright yellow solid, m.p. 135-1370C (dec).
EXAMPLE 30 9-Acetyl-4-benzeneaulphonyl-7-methyi-6 , 6a, 7,8,9, 9a-hexahydro-4H- indolo [6,5,4-cd] indole ethylene ketal
Ethane-1,2-diol (0.07 cm ) and dry benzene (2cm ) were heated in a Dean and Stark azeotropic distillation apparatus to remove all water. To the cooled anhydrous solution was added the 9-acetyl compound (Example 4) (0.05 g) and fused Ertoluenesulphonic acid (0.0025 g) and the mixture heated to reflux forl hours.
Dichloromethane (20cm3) and water (20cm3) were added and the product isolated as a yellow-white smear.
EXAMPLE 31 9-Acetyl-7-methyl-6, 6a, 7,8,9, 9a-hexahydro-411-indolo [6,5,4-cd] indole
Debenzenesulphonylation of the 9-acetyl compound (Example 4) (0.20 g) was achieved with potassium hydroxide in refluxing ethanol by the procedure previously described.
Purification on silica gel 60 eluted with chloroformmethanol (2:1) yielded the title compound as a white solid, m.p.
195-1980C (dec).
The compounds of the invention can be prepared in typical formulations, and for example the following are representative, the active ingredient being one of the pharmacologically active compounds.
EXAMPLE 32
Tablet
Active ingredient 100 mg
Dried starch 400 mg
Polyvinyl pyrrolidone 50 mg
Sodium carboxymethyl starch 50 mg
Stearic acid 20 mg
The active ingredient and starch are mixed together and massed with a solution of polyvinyl pyrrolidone in alcohol. The mass is extruded through a screen, dried, sized and mixed with sodium carboxymethyl starch and stearic acid prior to compression on a tablet machine. Tablets weighing 620 mg are obtained.
EXAMPLE 33
Capsules
Active ingredient 50 mg
Starch flowable 300 mg
Silicone fluid 5 mg A portion of the starch is mixed with the silicone fluid. To the powder is added the active ingredient and the remainder of the starch. This blended mixture is filled into hard gelatin capsules.
Claims (1)
- CLAIMA compound of formula:in which R2 is hydrogen, C1,4 alkyl or a protecting group, R3 is C14 alkyl or a protecting group, and X is hydrogen or -OX is a leaving group.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8726328A GB2199032B (en) | 1984-07-27 | 1987-11-10 | Eergoline derivatives useful as intermediates |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB848419278A GB8419278D0 (en) | 1984-07-27 | 1984-07-27 | Pharmaceutical compounds |
| GB8726328A GB2199032B (en) | 1984-07-27 | 1987-11-10 | Eergoline derivatives useful as intermediates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB8726328D0 GB8726328D0 (en) | 1987-12-16 |
| GB2199032A true GB2199032A (en) | 1988-06-29 |
| GB2199032B GB2199032B (en) | 1989-04-12 |
Family
ID=26288035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB8726328A Expired GB2199032B (en) | 1984-07-27 | 1987-11-10 | Eergoline derivatives useful as intermediates |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2199032B (en) |
-
1987
- 1987-11-10 GB GB8726328A patent/GB2199032B/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| GB2199032B (en) | 1989-04-12 |
| GB8726328D0 (en) | 1987-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1115271A (en) | Mercapto substituted-2,3,4,5-tetrahydro-1h-3- benzazepines | |
| EP0266349B1 (en) | Tricyclic indole derivatives, their manufacture and use as medicines | |
| IE870497L (en) | Tetrahydropyridin-3-carboxaldehyde oxime | |
| US3419547A (en) | Certain 10-basically substituted-5h-dibenzo[b,e,][1,4]diazepine compounds | |
| CS224646B2 (en) | Method for producing improved derivates of 3,4-dihydro-5h-2,3-benzodiazepine | |
| Gall et al. | Pharmacology of some metabolites of triazolam, alprazolam, and diazepam prepared by a simple, one-step oxidation of benzodiazepines | |
| US4841056A (en) | Substituted hexahydro-4H-indolo[6,5,4-cd]indoles | |
| US3751415A (en) | 2-nitro-11-(1-piperazinyl)-dibenz(b,f)(1,4)oxazepines | |
| NZ202036A (en) | 7-bromo-5-(2-halophenyl)-1h-2,3-dihydro-1,4-benzodiazepine derivatives and pharmaceutical compositions | |
| DE2156472A1 (en) | Process for the preparation of new diazepine derivatives | |
| EP0030351A2 (en) | Ergoline derivatives, their preparation and therapeutic composition containing them | |
| US4634708A (en) | Indolophenanthridines useful as dopaminergic and analgesic agents | |
| GB2199032A (en) | Pharmaceutical compounds and their preparation | |
| JPH0794432B2 (en) | Novel phenyl-, pyrrolidin-2-yl-substituted 5-membered heterocyclic compound, method for producing the same, and antipsychotic pharmaceutical composition containing the compound as an active ingredient | |
| EP0025941A1 (en) | Pyridazopyridazine derivatives, processes for their preparation and pharmaceutical compositions containing these pyridazopyridazine derivatives | |
| DE2030315A1 (en) | ||
| US4843073A (en) | 1-t-butyl ergolines useful in the treatment of cerebral insufficiency and senile dementia | |
| CA1070301A (en) | Triazolo-thieno-diazepine-1-ones, processes for their production and pharmaceuticals | |
| US3280145A (en) | New indole derivatives and their acid addition salts | |
| Kalaus et al. | Synthesis of Vinca alkaloids and related compounds. 37. Some new reactions of (.+-.)-C-norquebrachamine and its derivatives | |
| CA1037045A (en) | Quinolone derivatives and the preparation thereof | |
| KR810001976B1 (en) | Method for preparing triazolo-thieno-diazepin-1-one | |
| EP0575370B1 (en) | Process for the purification of lofepramine by crystallisation | |
| US3222368A (en) | Methylsulfinylmethyl ketone derivatives of substituted quinolizines | |
| US4032535A (en) | Triazolobenzodiazepines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 7732 | Case decided by the comptroller ** patent revoked (sect. 73(2)/1977) |